Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770637 · ClinicalTrials.gov registry record · Phase 2
Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
A Phase 2 study of Hyperinsulinemic Hypoglycemia, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 5
- Study locations
NCT03770637: Completed Phase 2 study of Hyperinsulinemic Hypoglycemia, sponsored by Xeris Pharmaceuticals.
NCT03770637 is a Phase 2 study of Hyperinsulinemic Hypoglycemia that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03770637, a Phase 2 study of Hyperinsulinemic Hypoglycemia, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial hypoglycemia. Twelve eligible subjects will be randomly assigned to receive Glucagon RTU or placebo at the first of two clinical research center (CRC) visits, followed by the other treatment at the second CRC visit. Subjects will be randomly assigned to either Glucagon RTU or Placebo for the duration of a 12-week Outpatient Stage. A follow-up safety assessment visit will occur 14 to 28 days after a subject's last dose of study drug.
Primary Outcome
Number of subjects with blood glucose \> 70 mg/dL
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Glucagon RTU
Study Locations (5)
Colorado
- University of Colorado-Denver - Aurora
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Joslin Diabetes Center - Boston
Minnesota
- Mayo Clinic- Rochester - Rochester
North Carolina
- Duke Early Phase Clinical Research - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2020-02-26 |
| Phase | Phase 2 |
What the finished NCT03770637 record still lists
NCT03770637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Hyperinsulinemic Hypoglycemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03770637 lists 5 locations in 5 states (Colorado, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03770637 about?
NCT03770637 is a clinical study titled "Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery". This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial hypoglycemia. Twelve eligible subjects will be randomly assigned to receive ...
What is the current status of trial NCT03770637?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2019-05-10. Estimated completion is 2020-02-26.
What conditions does trial NCT03770637 study?
This clinical trial studies the following conditions: Hyperinsulinemic Hypoglycemia.
What interventions are being tested in trial NCT03770637?
The interventions under investigation include: Placebo (OTHER), Glucagon RTU (DRUG).
Who is sponsoring clinical trial NCT03770637?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03770637 being conducted?
This trial has 5 study locations across Colorado, Maryland, Massachusetts, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03770637's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy